website at
. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary Statement Regarding Forward-Looking Information.
This news release contains certain statements which may constitute forward-looking statements or information (collectively, forward-looking statements ) regarding Hunter’s business development plans.
Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, including factors beyond Hunter’s control, and often contain words such as anticipate, believe, plan, estimate, expect, and intend, statements that an action or event may, might, could, should, will or be on track to be taken or occur, or other similar expressions. All statements, other
Parkland Corporation Announces February 2021 Dividend
/EIN News/ CALGARY, Alberta, Feb. 11, 2021 (GLOBE NEWSWIRE) Parkland Corporation (“Parkland”) (TSX:PKI) announces that a dividend of $0.1012 per share will be paid on March 15, 2021 to shareholders of record on February 22, 2021. The dividend will be an eligible dividend for Canadian income tax purposes. The ex-dividend date is February 19, 2021.
Enhanced Dividend Reinvestment Plan
Parkland s enhanced Dividend Reinvestment Plan ( Enhanced DRIP ) allows shareholders to reinvest their cash dividends to purchase additional Parkland shares from treasury at a 5% per share discount to the average of the daily volume weighted average trading prices during the Pricing Period. For further details on the Enhanced DRIP and the Pricing Period, please visit www.parkland.ca/en/investors/dividends.
The Lancet publishes Libtayo (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50% Libtayo was superior
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
Specialty Care sales grew 18.3%, driven by strong Dupixent
performance (+54.2% to €982 million).
Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH.
General Medicines declined 7.5%, reflecting lower U.S. Diabetes sales, COVID environment and portfolio streamlining.
CHC down 3.0% due to decreased sales of Cough & Cold related portfolio in Europe partially offset by Digestive Health brands.
Leveraged business EPS as the result of prioritization within R&D and continued execution on smart spending initiatives.
Sales down 2.4% and business EPS flat on a reported basis, as a result of the overall adverse impact from foreign currency rates.
Perspecta announces financial results for third quarter of fiscal year 2021
- Revenue of $1.13 billion
- Operating cash flow of $117 million
- Bookings of $0.9 billion (Q3 book-to-bill ratio of 0.8x; trailing-twelve-month book-to-bill ratio excluding NGEN SMIT impact of 1.2x)
News provided by
Share this article
Share this article
CHANTILLY, Va., Feb. 5, 2021 /PRNewswire/ Perspecta Inc. (NYSE:PRSP), a leading U.S. government services provider, today announced financial results for the third quarter of fiscal year 2021, which ended January 1, 2021.
As previously announced on January 27, 2021, Perspecta entered into a definitive merger agreement to be acquired by Peraton, a portfolio company of Veritas Capital Fund Management, L.L.C. Under the terms of the merger agreement, Perspecta stockholders will receive $29.35 per share in cash. The merger is subject to customary conditions, including approval by Perspecta stockholders as well as the receipt of regulatory approvals and